The patient died of acute liver failure; the maker of the gene therapy noted that the patient also had a recent ...

Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential.

Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for muscular dystrophy, sending company shares plummeting more than 25%. The young man died of acute ...

Elevidys, which costs $3.2 million for a one-time infusion, was the first gene therapy approved in the U.S. for Duchenne ...

Cambridge-based Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for muscular dystrophy, sending company shares plummeting in morning trading.

A patient has died while taking a closely watched gene therapy for muscular dystrophy. Sarepta Therapeutics announced the ...

Drugmakers are urging the Trump administration and EU officials to exclude medical goods from expanding tariffs wars ...

Her expertise is in personal finance and investing, and real estate. The total cost of a business is composed of fixed costs and variable costs. Fixed costs and variable costs affect the marginal ...

Learn about our editorial policies The required rate of return (RRR) and the cost of capital are key fundamental metrics in finance and investing. These measures—which vary in scope, perspective ...

Charlie’s gene therapy, Elevidys, is one of the newly approved ... one of the most common genetic errors we say: Good luck. The cost of delayed Duchenne diagnosis is both human and monetary.